Sir-Bourdeaut et al. [1] recently described 2 pediatric patients with chronic granulomatous disease (CGD) who developed chest infections caused by Propionibacterium acnes. We describe a 7-year-old boy with CGD who developed a Propionibacterium propionicus infection.
CGD is an inherited disease caused by defects in superoxyde-generating nicotinamide adenine dinucleotide phosphate oxidase of phagocytes [2] . Impairment of oxygen-dependent intracellular killing mechanisms results in severe infections with catalase-producing Staphylococcus aureus, Burkholderia cepacia, or Aspergillus species [3] .
In our patient, CGD was diagnosed at 3 months of age after an episode of suppurative cervical lymphadenitis. X-linked inheritance of CGD was supported by the finding of intermediate values with the nitroblue-tetrazolium (NBT) test (47% of neutrophils were NBT positive) of a blood sample from the patient's mother. He was given prophylactic cotrimoxazole; he was free of major infections. At 7 years of age, he was admitted to our institute because of chest-wall contusion. At admission he was febrile (temperature, 39ЊC) and tachydispneic (respiration rate, 50 breaths/ min). Laboratory values were as follows: erythrocyte sedimentation rate, 84 mm/h; hemoglobin, 147 g/L; WBC count, 52.0 ϫ 10 9 cells/L, with 45.2 ϫ 10 9 neutrophils/L; C-reactive protein, 237 mg/L (normal range, !10 mg/L). Chest radiography revealed a left-side pleural effusion. A thoracic CT scan showed microabscesses of the left lower lobe. Chest drainage yielded 300 mL of fibrinous exudate. Empirical antibiotic treatment with tobramycin and ceftazidime was started. The patient became afebrile 48 h later but pleural effusion persisted, and a thoracotomy was perfomed 2 weeks later. Pathological examination of the lung tissue specimen revealed microabscesses and granulomatous inflammation. Results of staining for mycobacteria and fungi were negative. Direct Gram staining of pleural fluid and lung biopsy specimens revealed non-acid-fast, gram-positive filamentous rods identified as P. propionicum. Isolates were sensitive to penicillin, cephalosporins, and vancomycin. We continued treatment with penicillin, and complete clinical remission was achieved 1 month later.
The most common causes of pneumonitis in patients with CGD are Aspergillus and Nocardia species and Burkholderia cepacia [3] . However, various opportunistic, catalase-producing microbes may infect patients with CGD [2, 3] . P. propionicus is a less common causative agent of a disease similar to actinomycosis [4] . Thoracic actinomycosis results from aspiration of pieces of infectious material from the teeth and may involve the chest wall, the lungs, or both. Intact mucosa are the first line of defense, because P. propionicus, like other anaerobes in the normal flora, must gain access to tissue with an impaired blood supply to establish an infection. Thus, it is possible that multiple episodes of chest trauma in our patient allowed development of this infection. In our patient, the clinical course and the response to antimicrobial treatment were similar to those in patients with CGD and P. acnes chest infection [1] . Bourdeaut et al. [1] emphasized the importance of the lung biopsy that led to correct diagnosis of this rare infection. Infections with Propionibacterium species have been reported in patients with trauma, in patients who had undergone surgery, and in patients with immunodeficiency [4] . Propionibacterium species are rarely associated with human disease but may cause serious, deep-seated infections in patients with CGD. Sir-I read the interesting letter by Cunha [1] that emphasized the suitability of doxycycline as a cost-effective alternative for treating patients with communityacquired pneumonia (CAP). I agree that the efficacy of doxycycline against Streptococcus pneumoniae should not be compared with that of tetracycline. However, I believe that 3 major issues about doxycycline are often overlooked. First, updated data on the pharmacokinetics of oral doxycycline remain both scarce and controversial. Indeed, whereas Cunha [1] reported peak serum doxycycline concentrations of ∼4 mg/mL after administration of a 100-mg oral dose, Sakellari et al. [2] observed mean peak serum concentrations of 2.35 mg/mL 2 h after administration of the same dose. Our experience with 6 healthy volunteers who received a 100-mg tablet is closer to that of Sakellari et al. [2] , because we observed a mean peak serum level of 1.37 mg/mL 2 h after administration of the dose (Bantar et al., unpublished data).
Second, the use of doxycycline for treating outpatients with CAP has probably been promoted on the basis of data published in some guidelines on the in vitro efficacy of this drug against penicillin-resistant strains of S. pneumoniae [3, 4] . However, to my knowledge, results of specific controlled clinical trials involving patients with CAP treated with oral doxycycline in an ambulatory manner nor pharmacodynamic studies of the efficacy of doxycycline against S. pneumoniae infection have not been published to date.
Third, recommendations on antimicrobial treatment for treating adults with CAP are highly influenced by the severity of illness, and the presence of bacteremia is seldom taken into account when selecting the primary drug [3] [4] [5] . This fact, together with results of clinical trials that demonstrated the overall efficacy of certain drugs, probably led some authorities to recommend that certain therapies be given orally for the treatment of low-risk CAP, even though some of these drugs (i.e., azithromycin and doxycycline) may reach poor serum levels or display only inhibitory activity [2, 6] . However, caution should be exerted for patients receiving treatment for pneumococcal bacteremia, because delay in achieving bactericidal serum levels could play a crucial role in allowing development of breakthrough pneumococcal bacteremia during the course of oral therapy in those at low risk for breakthrough infection, as observed with doxycyline in an earlier study [7] and with azithromycin in a more recent study [8] .
Although the overall incidence of pneumococcal bacteremia among patients with CAP is low (i.e., 10%-20%), several of these patients may belong to a low-risk class. Bantar et al. [5] assessed the distribution of the severity of illness index (as defined by the Pneumonia Outcomes Research Team [PORT] index) for 101 patients with bacteremic pneumonia enrolled in a number of clinical trials performed in Argentina, Chile, and Uruguay. Overall, 61 patients (60.3%) had a low-risk index (i.e., PORT I-III). It should be noted that, according to some guidelines, all of these patients would have been candidates for doxycycline therapy [3, 4] .
Furthermore, results of a comparative ex vivo pharmacodynamic study demonstrated that, even against a tetracyclinesusceptible pneumococcus strain, a single dose of oral doxycycline was only inhibitory during the first 8-h incubation period and was unable to inhibit bacterial growth after a 24-h incubation period in time-kill studies performed using serum samples obtained at 2, 4, and 6 h after dose administration (Bantar et al., unpublished data). Therefore, I strongly concur with Cunha [1] and recommend that a loading dose be used to initiate treatment if doxycycline is going to be administered, and I urge consideration of the fact that, although intravenous doxycycline has been suggested by some researchers to be a cost-effective option for treating hospitalized patients with CAP [9] , this suggestion might be not applicable when using standard oral therapy to treat patients with low-risk CAP, especially those with suspected pneumococcal bacteremia. There is no doubt that comparative clinical trials assessing the efficacy of doxycycline administered in the manner proposed by Cunha [1] will be useful to definitively establish the cost-effectiveness of this drug in the treatment of patients with low-risk CAP.
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